Mission’s DUB platform lands Pfizer deal, $15M series C extension July 6, 2020 By Nuala Moran No Comments LONDON – Mission Therapeutics Ltd. has sealed a discovery deal with Pfizer Inc. around its small-molecule protein degradation platform and raised $15 million as an extension to its series C, with Pfizer Ventures leading the round.Read More